Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Serological assays for emerging coronaviruses: Challenges and pitfalls

Benjamin Meyer, Christian Drosten, Marcel A. Müller*

Institute of Virology, University of Bonn Medical Centre, Bonn, Germany

A R T I C L E   I N F O

Article history:
Available online 23 March 2014

Keywords:
SARS-CoV
MERS-CoV
Reservoir
Serology
Antibody
Cross-reactivity

A B S T R A C T

More than a decade after the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2002/2003 the occurrence of a novel CoV termed Middle East respiratory syndrome (MERS) CoV challenges researchers and public health authorities. To control spread and finally contain novel viruses, rapid identification and subsequent isolation of infected individuals and their contacts is of utmost importance. Next to methods for nucleic acid detection, validated serological assays are particularly important as the timeframe for antibody detection is less restricted. During the SARS-CoV epidemic a wide variety of serological diagnostic assays were established using multiple methods as well as different viral antigens. Even though the majority of the developed assays showed high sensitivity and specificity, numerous studies reported on cross-reactive antibodies to antigens from wide-spread common cold associated CoVs. In order to improve preparedness and responsiveness during future outbreaks of novel CoVs, information and problems regarding serological diagnosis that occurred during the SARS-CoV should be acknowledged.

In this review we summarize the performance of different serological assays as well as the applicability of the two main applied antigens (spike and nucleocapsid protein) used during the SARS-CoV outbreak. We highlight challenges and potential pitfalls that occur when dealing with a novel emerging coronavirus like MERS-CoV. In addition we describe problems that might occur when animal sera are tested in serological assays for the identification of putative reservoirs. Finally, we give a recommendation for a serological testing scheme and outline necessary improvements that should be implemented for a better preparedness.

© 2014 Elsevier B.V. All rights reserved.

1. Introduction

In 2002/2003, a new disease emerged in Southeast Asia that was subsequently termed severe acute respiratory syndrome (SARS). A previously unknown coronavirus (CoV) was identified as the etiological agent (Drosten et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003). It was only the concerted efforts of public health authorities that made it possible to break the chain of transmission. No new cases have been reported since May 2004. Overall, SARS-CoV infected 8422 people, of whom 916 died, giving a case fatality ratio of about 11% (Chan-Yeung and Xu, 2003). Before the emergence of SARS-CoV, human pathogenic CoVs (HCoVs) such as HCoV-OC43 and HCoV-229E were known to cause mild upper respiratory diseases contributing to 5–30% of the seasonal common cold cases (Isaacs et al., 1983; Larson et al., 1980; Monto, 1974). This explains why, globally, more than 90% of the population has antibodies against the common cold CoV (Gorse et al., 2010).

SARS-CoV belongs to the Coronaviridae family within the order of Nidovirales. It harbors one of the largest known positive-strand RNA genomes comprising about 29 kb (Rota et al., 2003). The first two-thirds of the genome contain nonstructural proteins (NSP) that are well conserved among different CoV species (Rota et al., 2003). The NSPs include the RNA-dependent RNA polymerase and form the main part of the transcription/replication machinery. The last third of the genome encodes mainly the four structural proteins: spike (S), membrane (M), envelope (E) and nucleocapsid (N) (Rota et al., 2003). Interspersed between the structural proteins are group–specific open reading frames (ORFs) encoding a subset of accessory proteins with mostly unknown function (Narayanan et al., 2008). In the case of SARS-CoV, it was shown that, apart from the four structural proteins, some of the NSPs as well as the accessory proteins p3a and p7a, are incorporated into virions and may elicit an immune response in infected patients as it was shown for NSP13 (Leung et al., 2004; Neuman et al., 2008; Schaecher et al., 2007).
Diagnostic assays for SARS-CoV detection were rapidly developed after the identification of the virus. Testing of suspected cases helped considerably to contain the outbreak and understand the rapid disease progression that was observed in some of the patients. SARS patients had detectable viral RNA between three and 30 days after the first symptoms appeared, with high viral loads in lower respiratory tract and fecal samples. Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) assays were the first assays that helped identify and subsequently isolate patients who were actively shedding the virus (Drosten et al., 2003). It was reported that viral RNA could be detected by qRT-PCR up to 30 days post onset of illness (dpoI) (Chan et al., 2004a). However, detection rates by these early qRT-PCR assays were often low as they relied on sampling during virus shedding and proper handling of samples (Yam et al., 2003). The specificity of the qRT-PCR assays has also been questioned because of the potential for nucleic acid contamination in the laboratories where many SARS-CoV samples were processed (Patrick et al., 2006).

As a consequence, the development of serological assays became crucial at the time. Many laboratories worldwide generated in-house assays using either virus-derived antigen or recombinant structural CoV proteins. For all laboratories, proper validation of serological assays was highly challenging because of its reliance on numerous well-characterized positive and negative serum samples. Furthermore, the exchange of patient serum samples was a major challenge during the outbreak for logistic and ethical reasons. Assay sensitivity (the number of positive samples that could be determined correctly) and specificity (measured by the number of negative samples that could be identified correctly) were therefore difficult to determine. Consequently, an external quality assurance study revealed that many laboratories had difficulties with SARS-CoV seroanalytics (Niedrig et al., 2005). In particular, the high seroprevalence in the population of antibodies against the common cold CoV combined with the presence of cross-reactive antibodies against conserved parts of the immunogenic CoV proteins could have contributed to false positive results.

Nevertheless, as antibodies can be detected over a long period, developing reliable post-infection serological assays for SARS-CoV became a high priority. Serodiagnostics assays were applied to address epidemiological questions about transmission patterns, to observe silent infections, to analyze disease progression and to identify the origin of SARS-CoV. Patients usually developed IgM and IgG antibodies within 17–21 dpoI (Woo et al., 2004b). To identify infected contacts, including those that are asymptomatic, it is recommended to analyze paired serum samples. Ideally, samples should be taken on day 0 and day 42 post exposure since it was shown that seroconversion of IgG or IgM occurred during that period (Chen et al., 2004a). According to the WHO criteria for serological diagnosis, a patient was considered to have seroconverted if one of the following statements were true: “Negative antibody test on acute-phase serum followed by positive antibody test on convalescent-phase serum tested in parallel” or a “Fourfold or greater rise in antibody titer between acute- and convalescent-phase sera tested in parallel” (WHO, 2004). Of note, WHO further recommended using a virus neutralization test (VNT) to exclude serological cross-reactions with other human or animal CoVs (WHO, 2004).

In this review, we summarize the various types of serological assays that were developed during the SARS-CoV outbreak and analyze the challenges and potential pitfalls of serodiagnostics. It should be acknowledged that the multitude of developed assays and the lack of standardized procedures and assay validation make it difficult to directly compare all studies. Finally, we discuss the implications and challenges facing serodiagnosis of the novel Middle East respiratory syndrome (MERS-CoV).

2. Testing parameters: IgM vs. IgG subclasses

Testing for different immunoglobulin (Ig) subclasses is common in serodiagnostics. Being pentameric with ten antigen-binding sites, IgM is characterized by a higher antigen avidity but lower antigen affinity than IgG (Murphy et al., 2008). As antibodies of IgM subclass are usually the first to develop following a primary challenge (Murphy et al., 2008), IgM is considered a parameter of the early phase of infection. However, Woo et al. (2004b) found that IgM could not be detected earlier than IgA and IgG subclass antibodies in SARS-CoV serodiagnostic assays. The low affinity of IgM antibodies also carries the increased risk of cross-reactivity with antigenically related epitopes, which are common in CoVs. IgM detection has an added value for CoV serodiagnostics as it is only present in very recently infected patients, but does not allow differential diagnosis. In contrast IgG antibodies comprise a higher specificity than IgM and can be detected even years after the infection. In this review, we therefore focus on studies describing assays for the detection of IgG antibodies.

3. Virus-based serological assays

During the outbreak of SARS-CoV, a wide variety of serological assays were established, including immunofluorescence assays (IFAs), enzyme-linked immunosorbent assays (ELISAs) and Western blot (WB) analysis.

Conventional IFAs (cIFAs) using virus-infected African green monkey kidney cells (Vero E6) spotted on glass slides and ELISAs using extracts or supernatant of infected cells were among the first assays used in serological diagnosis of SARS-CoV (Chan et al., 2004b; Chen et al., 2004a; Hsieh et al., 2003; Ksiazek et al., 2003; Peiris et al., 2003; Wu et al., 2004). Both cIFAs and ELISAs for SARS-CoV were relatively easy to set up for experienced laboratories, as they primarily only required susceptible cell cultures and the virus. An obvious disadvantage of virus-based serological assays is the need for a biosafety level (BSL) 3 facility. In addition, IFAs can neither be properly standardized because the interpretation of fluorescence staining patterns is subjective, nor are they appropriate for high-throughput screening. In the case of ELISAs, antigen production can be an obstacle if it necessitates ultra centrifugation under BSL3 conditions. Ensuring that the antigen is properly inactivated can also be problematic. Ultimately, validation of the ELISA is dependent on access to a well-characterized serum collection for the determination of the assay-specific cut-off value.

A detailed summary of studies applying SARS virus-based cIFAs and ELISAs is given in Table 1. Since SARS-CoV seroconversion generally occurred during the second week of illness (Hsieh et al., 2003; Ksiazek et al., 2003), only those studies in which sera was taken at least 14 dpoI are included in this overview. In the majority of cases, patient serum was tested in assays using virus-derived antigens. Most of the studies found that serum from between 85% and 100% of previously diagnosed SARS patients tested positive (Table 1, column 3), suggesting that the cIFA and ELISA used were highly sensitive. Of note, the studies with the most reliable results were those that used a large number of patient serum samples (n=90; Chan et al., 2004b) and n=224; Wu et al. (2004)), which found that 98.2% and 99.1%, respectively, were positive.

Specificity of serological assays is vital to avoid false positive diagnoses. Critically, some of the HCoVs are antigenically closely related (Bradburne, 1970). This means, in combination with the observed high prevalence of HCoVs, such as HCoV-OC43, HCoV-229E and HCoV-NL63, in the population (Che et al., 2005; Dijkstra et al., 2012), that the specificity of the SARS-CoV assay is of particular concern. We therefore analyzed and summarized the rate of false positive results found in serological studies and differentiated
between the two types of control groups used; sera from individuals with non-SARS respiratory infection or in contact with SARS patients, or from healthy donors (Table 1, columns 4 and 5). One limitation of this analysis is that, in most of the studies, negative control sera were obtained from respiratory infection patients or blood donors, and therefore the inclusion of unidentified SARS cases cannot be completely discounted. Nevertheless, the detection rate of false positive samples gives a rough estimate of the specificity and allows the performance of these assays to be evaluated. In the various case control studies that were conducted during or after the SARS outbreak, cIFAs and viral antigen-based ELISAs detected between 0% and 12.2% false positives (Table 1, columns 4 and 5). assay outcomes were highly dependent on the study design and the negative cohort selected. Notably, in one study, the rate of false positive results of cIFA increased to 12.2% when a virus neutralization assay was used as a gold standard (Wu et al., 2004). This could be explained by a lack of neutralizing capacity of certain cIFA-positive sera or indeed by cross-reactivity of sera with antigens from related HCoV in the cIFA.

A study by Guan and colleagues clearly emphasized the problems encountered when using whole virus-derived antigen. They applied whole viral lysates as antigen in WB analysis and observed a marked difference in reactivity to individual CoV proteins. N protein reactivity was detected in all SARS patient sera, indicating a sensitivity of 100%; however, it also gave false positive results in 17–66% of cases depending on the type of negative control subset tested. By contrast, serum from only 78% of SARS patients reacted with the S protein, but with no false positives, indicating that S protein detection by WB has a higher specificity. Interestingly, when, in one study, a recombinant glutathione S transferase (GST)-tagged N protein lacking a highly conserved part was used as the target there were no false positives. This clearly demonstrates that serological assays applying SARS-CoV-derived antigens should be interpreted with caution.

4. Recombinant protein-based assays

Serological assays that rely on recombinant proteins as antigen are widely used in laboratory diagnostics (Ecker et al., 1996; Farber et al., 1993). As a prerequisite, single immunogenic viral genes have to be cloned into prokaryotic or eukaryotic expression plasmids to produce proteins in bacterial or mammalian cell cultures. They have a major advantage as they do not require BSL3 containment and are appropriate for assay standardization if protocols are closely followed. In SARS-CoV, the N and S are the major immunogenic proteins (Qu et al., 2005). Recombinant versions of both proteins have been used in IFAs, ELISAs and WB analysis (Table 2). Nevertheless, development and validation of assays using recombinant proteins may take longer and is also technically demanding as the necessary molecular cloning, transfection and protein purification techniques must first be optimized.

The N protein, as a major immunogenic protein of SARS-CoV (Qu et al., 2005), was widely used in recombinant serological assays. Its small size and lack of glycosylation sites make it easy to clone and purify in vast quantities from bacteria. Serum from between 73% and 100% of SARS patients reacted with the complete or partial N protein in ELISAs or WB analyses indicating that these assays had high sensitivity (Table 2). No marked difference could be found between studies using a partial or complete N protein as antigen. By contrast, the rate of false positive results differed grossly between the individual studies. Most studies claimed that N protein-based ELISA and WB analysis detected only between 0% and 5.7% false positives in the sera of the negative control groups (Table 2), suggesting a low to moderate specificity. Of note, Woo et al. (2004a) were able to show that 29 of 33 sera that were false positive in an N protein-based ELISA were not reactive in a confirmatory WB assay using a SARS spike polypeptide. Therefore these sera were confirmed to be truly false positives, making this study more reliable than others. Conversely there are several reports showing that cross-reactivity with other human pathogenic CoVs occurs when using N protein-based assays (Che et al., 2005; Maache et al., 2006; Woo et al., 2004c). Of particular note is one study in which the N protein completely failed to differentiate serum from SARS patients and healthy individuals (Maache et al., 2006). These findings further highlight the complexity of serum diagnostics for CoVs and emphasize that a valid diagnosis cannot rely on reactivity to a single antigenic protein.

The other major immunodominant protein of SARS-CoV is the S protein (Qu et al., 2005) which has been used in IFAs, ELISAs and WB analysis as well as for the generation of pseudotyped particles to develop a biosafe VNT (Fukushi et al., 2008; Hofmann et al., 2004). The majority of neutralizing antibodies were found to be directed against the S protein (Buchholz et al., 2004). For IFA, it was possible to use both full-length S, stably expressed in mammalian cells (Tan et al., 2004), and a fragment (amino acids aa) 441–700 expressed in insect cells using baculovirus (Manopo et al., 2005). By contrast, because of the technical difficulties in expressing the full-length protein in bacteria, only fragments were used in ELISAs and WB analysis.

### Table 1

| Antigen | Assay | SARS sera (>14 dpoi) | Control sera from respiratory patients or SARS contacts | Control sera from healthy donors | Reference | Comment |
|---------|-------|----------------------|------------------------------------------------------|---------------------------------|-----------|---------|
| Whole Virus | IFA | 89/90 (98.8) | 0/540 (0) | 0/635 (0) | Chan (2004, #6) | 24 control sera were excluded due to unspecific reaction |
| Whole Virus | IFA | 34/34 (100) | n.d. | 1/100 (1) | Che (2005, #9) | |
| Whole Virus | IFA | 6/7 (85.7) | n.d. | 0/10 (0) | Hsu (2003, #22) | |
| Whole Virus | IFA | 10/10 (100) | 0/27 (0) | 0/384 (0) | Kisiazek (2003, #66) | |
| Whole Virus | IFA | 46/46 (100) | 0/40 (0) | 0/16 (0) | Leung (2004, #29) | |
| Whole Virus | IFA | 37/37 (100) | 0/80 (0) | 0/200 (0) | Peiris (2003, #86) | |
| Whole Virus | ELISA | 22/224 (99.1) | 30/245 (12.2) | n.d. | Wu (2004, #60) | Using VNT as gold standard |
| Whole Virus | ELISA | 10/10 (100) | 0/27 (0) | 1/384 (0.3) | Kisiazek (2003, #66) | |
| Whole Virus | ELISA | 42/46 (91.3) | 3/40 (7.5) | 1/38 (2.6) | Leung (2004, #29) | |
| Whole Virus | ELISA | 17/20 (85) | 0/20 (0) | 2/40 (5) | Wang et al. (2004, #54) | |
| Whole Virus | ELISA | 220/224 (98.2) | 3/245 (1.2) | n.d. | Wu (2004, #60) | Using VNT as gold standard |

dpoi, days post onset of illness; IFA, immunofluorescence assay; n.d., not determined; ELISA, enzyme-linked immunosorbent assay; VNT, virus neutralization test.

* Calculated from information given in the paper.

* No differentiation between acute and convalescent sera.
### Table 2

| Antigen | Assay | SARS sera (≥ 14 dpi unless otherwise indicated) % | Control sera from respiratory patients or SARS contacts % | Control sera from healthy donors % | Reference | Comment |
|---------|-------|---------------------------------------------------|------------------------------------------------------|----------------------------------|-----------|---------|
| N       | ELISA | 6/6 (100)d                                       | 0/73 (0)d                                          | 0/20 (0)d                       | Carattoli (2005, #3) | Conflicting information: in the text two control sera mentioned as positive Values depend on assay settings |
| N       | ELISA | 56–61/76 (73.6–80.2)d                            | 1–4/100 (1–4)d                                     | 8–23/1451 (0.6–1.6)d           | Guan (2004a, #14) |         |
| N partial | ELISA | 74/74 (100)c                                     | n.d.                                               | 1/210 (0.5)c                    | Guan (2004b, #15) | Highly conserved motif deleted in N protein |
| N partial | ELISA | 41/46 (90.1)c                                    | 2/40 (5)c                                          | 2/35 (5.7)c                     | Leung (2004, #29) | N-terminal half |
| N       | ELISA | 301/327 (92)c                                    | 4/2049 (0.2)c                                      | 3/1700 (0.2)c                   | Liu (2004, #73) |         |
| N       | ELISA | 121/135 (89.6)c                                  | 0/64 (0)c                                          | 1/940 (0.1)c                    | Shi (2003, #44) | Antigen capture ELISA |
| N       | ELISA | 100/106 (94.3)c                                  | 33/828 (4.0)c                                     | 7/149 (4.7)c                    | Woo (2004, #87) |         |
| N       | WB    | 34/34 (100)d                                     | n.d.                                               | 2/100 (2)c                      | Che (2005, #9) | 29/33 false positive sera confirmed as false positives |
| N partial | WB    | 40/40 (100)d                                     | 0/100 (0)d                                        | 0/50 (0)d                       | Guan (2004, #16) |         |
| N partial | WB    | 73/77 (94.8)c                                    | 4/134 (3)c                                        | 0/160 (0)c                      | He (2004a, #18) | 195 C-terminal aa |
| N       | WB    | 30/30 (100)c                                     | n.d.                                               | 48/48 (100)c                    | Maache (2006, #33) |         |
| N       | WB    | 74/74 (100)c                                     | n.d.                                               | 0/99 (0)c                       | Tan (2004, #49) |         |
| N       | WB    | 10/10 (100)c                                     | n.d.                                               | n.d.                            | Wang et al. (2005, #53) |         |
| S partial | IFA   | 15/15 (100)c                                     | 0/42 (0)c                                          | 0/100 (0)c                      | Manopo (2005, #36) | aa 441–700 |
| S       | IFA   | 74/74 (100)c                                     | n.d.                                               | 0/100 (0)c                      | Tan (2004, #49) |         |
| S partial | ELISA | 6/46 (13)c                                       | 5/40 (12.5)c                                      | 2/38 (5.3)c                     | Leung (2004, #29) | app. 315 C-terminal aa |
| S partial | ELISA | 56/93 (60.2)c                                    | n.d.                                               | 2/148 (1.4)c                    | Woo (2005, #59) | aa 14–667 |
| S1      | WB    | 30/30 (100)c                                     | n.d.                                               | 0/48 (0)c                       | Maache (2006, #33) | aa 14–760 |
| S2      | WB    | 26/30 (86.7)c                                    | n.d.                                               | 0/48 (0)c                       | Maache (2006, #33) | aa 761–1190 |
| S1 subunit | WB   | 15/20 (75)c                                      | 6/20 (30)c                                        | 6/40 (15)c                      | Wang et al. (2004, #54) |         |
| S2 subunit | WB   | 17/20 (85)c                                      | 3/20 (15)                                        | 0/40 (0)c                       | Wang et al. (2004, #54) |         |
| S1      | WB    | 5/10 (50)c                                       | n.d.                                               | n.d.                            | Wang et al. (2005, #53) | aa 14–403 |
| S2      | WB    | 3/10 (30)c                                       | n.d.                                               | n.d.                            | Wang et al. (2005, #53) | aa 370–770 |
| S3      | WB    | 7/10 (70)c                                       | n.d.                                               | n.d.                            | Wang et al. (2005, #53) | aa 738–1196 |

dpi, days post onset of illness; N, SARS-CoV nucleocapsid protein; ELISA, enzyme-linked immunosorbent assay; n.d., not determined, WB, Western blot analysis; S, SARS-CoV spike protein; IFA, immunofluorescence assay; app., approximately.

* a Calculated from information given in the paper.
* b Includes 400 healthy blood donations from March–May 2003 since contact to SARS patients could not be excluded.
* c 4–71 dpi.

In general, antibodies directed against the S protein appeared later in infection than those directed against the N protein (Tan et al., 2004; Woo et al., 2005), indicating that S protein–based assays may be preferable for use with convalescent sera. Overall, reactivity of SARS patient sera with S protein differed grossly between different studies and types of assays, ranging from very low (13%) in one study (Leung et al., 2004) to 100% in several other studies (Table 2). There was a marked difference between detection rates with IFAs (100%), ELISAs (13–96%) and WB analysis (40–100%) (Table 2). The advantage of an IFA can be explained by its use of transfected cells that facilitate correct folding and post-translational modifications (e.g., glycosylation) of the S protein, whereas an ELISA and WB analysis use only denatured linear forms without proper glycosylation. For glycoprotein 120 (gp120) of the human immunodeficiency virus (HIV), it was shown that altered glycosylation patterns influence the host immune response (Grundner et al., 2004). Therefore patients that produce antibodies recognizing conformational epitopes or glycosylation-dependent epitopes of the S protein could be tested as false negatives in an ELISA or WB analysis. That ELISAs and WB analysis are only able to use S protein fragments, as mentioned above, provides a plausible explanation for the variable results found between different assays.

Reactivity of negative control sera to the S protein varied widely between individual studies. Two studies using an IFA to test a sizeable control group of 100 and 142 sera did not detect any false positives (Table 2), which is indicative of the high specificity of the assays. By contrast, ELISAs and WB assays reported between 0% and 30% false positive results, although most studies used control groups of less than 60 sera making them less reliable to estimate the true performance of the assays. Interestingly, the only ELISA-based study that used a rather large control group (148 healthy donors), found only two false positive serum samples (Woo et al., 2005). These results suggest that IFAs using the complete S protein have a specificity advantage over ELISAs or WB assays.

5. Cross-reactivity and cross-neutralization among coronaviruses

Immunogenic proteins of closely related viruses that share common structural or linear epitopes can elicit cross-reactive and cross-neutralizing antibodies in the host. That both occur with CoVs has been recognized for many decades (Bradburne, 1970), and was reflected by the former classification of CoVs into serogroups (McIntosh et al., 1969; Monto, 1974).

As a result assays that used full virus particles or extracts of infected cells as antigen encountered several problems. Two studies reported the appearance of bands at molecular weights of 60 and/or 97 kDa in WB assays using crude viral lysates that could not be attributed to structural proteins (Guan et al., 2004c; Leung et al., 2004). It was speculated that these bands might represent NSPs recognized by SARS patient sera. In fact, it was shown that some NSPs and accessory ORF-encoded proteins can be incorporated into viral particles (Neuman et al., 2008) and are possibly able to elicit an immune response. Indeed, reactive antibodies against SARS-CoV proteins 3a and 9b have been demonstrated in SARS patients by protein micro array (Qiu et al., 2005). Antibodies directed against
considered NSPs or ORF proteins could contribute to false positive results in assays using whole virus as antigen. In addition, conserved structural proteins such as the N protein are produced at high levels in infected cells and viral particles, further increasing the potential for cross-reactivity between different CoVs. The influence of the N protein in serological assays will be outlined in detail below.

Particularly when using denatured antigens in serodiagnostic assays, cross-reactivity is more likely to occur when the applied target proteins are conserved among related viruses. To estimate the rate of conservation of the immunogenic proteins N and S, we analyzed the percentage of aa identity between all HCoV comprising of the genera alpha- and beta-CoV (Table 3; first column). Pairwise analysis of complete N sequences revealed that the SARS-CoV N protein had 25–29% aa identity with Alpha-CoV and 33–47% with the more closely related Beta-CoV. By comparison, the complete S protein sequence showed a lower degree of conservation with 23–25% aa identity with Alpha-CoV and around 29% with Beta-CoV. However, as antibodies are produced against the exposed domains of three-dimensional proteins, the overall degree of aa conservation alone cannot predict the occurrence of cross-reactivity. To gain a fuller picture, we therefore analyzed the available information on conserved aa sequences within known immunodominant regions of SARS-CoV N and S protein (Table 3). A study by Chen and colleagues revealed four immunodominant regions in the N protein termed EP1 aa 51–71, EP2 aa 134–208, EP3 aa 249–273 and EP4 aa 349–422 (Chen et al., 2004b). Upon comparison with other human pathogenic Beta-CoVs, one immunodominant region of the N protein showed a low degree of conservation (11–28%) and three regions showed a high degree (40–67%) (Table 3). In addition, Rota et al. found a very conserved motif of eight amino acids present in the N protein of all CoVs, including animal CoVs (Rota et al., 2003).

The S protein harbors five different immunogenic sites at aa positions 9–71, 171–224, 271–318, 528–635 and 842–913 (He et al., 2004b). Compared to human pathogenic Beta-CoVs, three immunodominant regions of the S protein show a low degree of conservation (9–26%), one region shows a medium degree (33–42%), and one region shows a high degree (47–55%). Taken together, these findings may explain why N protein-based serological assays are more often associated with cross-reactivity than S protein-based assays.

There are several studies that address the question of whether there is cross-neutralization between related CoVs. Cross-neutralization has been shown between closely related animal CoVs, as in transmissible gastroenteritis virus (TGEV) and feline infectious peritonitis virus type 2 (Horzinek et al., 1982) that have around 95% identity in the C-terminal 1150 aa of the S protein, and also HCoV-OC43 and bovine CoV (BCoV) (Gerna et al., 1981). Interestingly, even HCoV-HKU1, which is closely related to HCoV-OC43, is neither neutralized by HCoV-OC43-reactive sera, despite an aa identity of 64.5% in the S protein, nor by sera reactive with the more distantly related HCoV-229E or SARS-CoV (Chan et al., 2009). Similar results were found for the closely related CoVs HCoV-NL63 and HCoV-229E (Hofmann et al., 2005). To our knowledge, there is only one study describing cross-neutralization between HCoVs, namely of MERS-CoV using SARS-CoV reactive sera. However, it should be noted that neutralizing titters were very low (1:10), indicating that an assay-specific cut-off should be determined with well-defined reference sera to avoid false positive results (Chan et al., 2013). In conclusion, these data clearly show the value of VNTs as a tool to differentiate even between closely related CoVs and reaffirms their status as the gold standard in serological diagnostics.

To provide a valid serological diagnosis of infection with CoVs, it is vital to rule out cross-reactivity and cross-neutralization by using a second confirmatory assay. Widely accepted confirmatory assays like the VNT, which was recommended by WHO during the SARS outbreak (WHO, 2004), are labor-intensive leading to a high workload in diagnostic laboratories and subsequently to slow sample processing. The latter, in particular, is unfavorable in an outbreak situation when rapid identification of infected individuals and their contacts is necessary to contain the infectious agent. Establishing highly specific primary serological screening assays that avoid false positive results, and thus the need for further confirmation, is therefore an important goal.

### 6. Serological assays for animal screening

Serological assays have been used successfully as a pre-screening tool for virus discovery (Burbelo et al., 2012; Drexler et al., 2013; Muller et al., 2007; Peel et al., 2013). Antibody detection assays are particularly valuable because short phases of virus shedding or poor sample quality decrease the chances of detecting nucleic acids. In addition, they allow the distribution of pathogens in various species and the antigenic relatedness with already known pathogens to be defined (Drexler et al., 2013, 2012). Importantly, testing of livestock and wild animals can help to trace the source of infection during an outbreak of a zoonotic virus (Li et al., 2005). The identification of the animal reservoir allows the pathogen to be contained by interrupting the chain of transmission, for example, by shutting down animal markets or culling infected animals. This has been a successful approach with outbreaks of avian influenza and SARS-CoV (Kan et al., 2003; Tam, 2002; Tu et al., 2004; Watts, 2004).

A zoonotic origin of SARS-CoV was suspected early on as the first cases occurred among people handling wild exotic animals in Guangdong Province, China (Zhong et al., 2003). Shortly afterwards Guan and colleagues acquired the first evidence, using RT-PCR and a VNT, that Himalayan palm civets (Paguma larvata) and raccoon dogs (Nyctereutes procyonoides) harbor a SARS-CoV strain that is 99.8% identical to the human SARS-CoV strain (Guan et al., 2003). The lack of viral genetic diversity in positive animals, along with the fact that wild and other farmed palm civets were SARS-CoV seronegative (Tu et al., 2004), indicated that palm civets were not the natural reservoir of SARS-CoV. The search for the source of SARS-CoV continued by screening hundreds of animals from a multitude of species (Poon et al., 2005). A decade later the natural reservoir of SARS-CoV was eventually confirmed to be Rhinolophus sinicus bats in China (Ge et al., 2013). Valuable hints that facilitated the identification of the SARS-CoV reservoir were already provided in late 2005. Two studies found closely related SARS-CoV in Chinese rhinolophid bats in Asia by RT-PCR and serological methods (Lau et al., 2005; Li et al., 2005) while another study found more distantly related CoVs in other bat families (Poon et al., 2005). Li et al. (2005) used two different ELISAs, recombinant SARS-CoV N protein- and whole virus antigen-based, and detected a seroprevalence between 28% and 71% depending on the bat species. The second study by Lau et al. (2005) used an ELISA and WB analysis based on recombinant N protein derived from a bat SARS-like CoV and found a seroprevalence of 84% (ELISA) and 67% (WB) in bats. A marked difference between these two studies was observed in the neutralizing activity of bat sera toward human SARS-CoV. While Lau et al. could detect neutralizing antibodies in some bat sera (42%), Li et al. found no neutralizing activity despite positive serum titters by ELISA of up to 1:6400. Despite these differences, both studies indicated that there was a high level of cross-reactive antibodies when complete virus antigen- and recombinant N protein-based assays were used. VNTs showed a higher specificity, even for these closely related CoVs.

Several follow-up studies in bats were conducted after these findings. The first evidence of CoV in African bats came from the detection of antibodies that reacted against SARS-CoV proteins (Muller et al., 2007). Different serological assays were employed
including a SARS-CoV protein–based ELISA, a cIFA using SARS-CoV infected cells and WB assays using either recombinant N or S protein or whole virus antigen (Muller et al., 2007). In this case, VNT revealed that African bats harbored antibodies that cross-reacted with different SARS-CoV antigens but were not able to neutralize SARS-CoV. In subsequent studies, we and others found that both Alpha- and Betacoronaviruses are highly diverse in African bats (Pfefferle et al., 2009; Quan et al., 2010), including close ancestral relatives of HCoV-229E and distant relatives of SARS-CoV. This example shows how the detection of cross-reactive bat serum antibodies against SARS-CoV antigen resulted in the discovery of highly diverse bat CoVs including relatives of SARS-CoV.

In conclusion, most assays performed well with animal sera. However, outcomes have to be evaluated cautiously as testing of animal sera adds another level of complexity. Animals may harbor antibodies against unidentified CoVs that can cross-react with the target antigen especially without knowing the degree of epitope conservation between test antigen and the unidentified CoV. In many cases, secondary detection antibodies are not always available or their performance in serological assays has not been validated. This is particularly true when human serodiagnostic assays are modified for use in animal screening. In the absence of viral nucleic acids, outcomes of serological animal screening should be interpreted cautiously and should only be used as an initial indicator for targeted follow-up studies.

### 7. Diagnostics for newly emerged MERS-CoV

In June 2012, a previously unknown CoV, now termed MERS-CoV, emerged in the Middle East (Zaki et al., 2012). To date, 180 people have been infected, of whom 77 have died (WHO, 2014), resulting in a case fatality ratio of 43%. So far, the virus is only endemic in the Middle East with only a few cases imported into countries outside this region (Bermingham et al., 2012; Buchholz et al., 2013; Drosten et al., 2013; Guery et al., 2013; HPA, 2013; Puzelli et al., 2013).

Similar to the SARS outbreak, the first diagnostic assays, including PCR and serological, were developed rapidly (Corman et al., 2012a, 2012b). Different serological assays were established including cIFAs using virus-infected cells, IFAs using VERO cells expressing recombinant N or S protein of MERS-CoV, as well as a WB analysis of lysates from cells expressing recombinant N or S protein (Corman et al., 2012b). A cell-free protein microarray was developed that uses the correctly folded and glycosylated S1 fragment of the MERS-CoV S protein as antigen (Reusken et al., 2013a). Finally, MERS-CoV– and S protein-pseudotyped viruses were used in neutralization assays (Buchholz et al., 2013; Drosten et al., 2013; Gierer et al., 2013a; Perera et al., 2013).

A major problem that faced all groups at the time of assay development was the need for a well-characterized sample collection to enable thorough validation. This should include defined positive sera for all known human pathogenic CoVs and MERS-CoV convalescent sera along with negative control groups. As only a very small number of positive sera were available at the time of testing, determination of assay sensitivity currently requires more rigorous validation. Assay specificity has been addressed in all studies. Similar to the SARS-CoV serological assays, using whole virus or recombinant N protein gave false positive results for IgM detection (Buchholz et al., 2013). In another study, 356 serum samples including those from 226 slaughterhouse workers in Saudi Arabia were screened using a cIFA followed by a recombinant S protein-based IFA and a VNT for confirmation. The cIFA in this study produced a significant number of false positives that required exclusion by confirmatory neutralization assay (Aburizaiza et al., 2013). Another study conducted in Saudi Arabia made use of MERS-S pseudotyped lentiviruses to test for virus–neutralizing antibodies (Gierer et al., 2013b). HCoV-NL63 S pseudotyped viruses were used as controls. All 268 tested serum samples were negative for MERS-CoV neutralizing antibodies. There was no unspecific cross-neutralization of MERS-S pseudotyped viruses by NL63-positive sera. Another study compared conventional VNT with the S pseudotyped lentivirus–based NT. In total, 1343 human serum samples collected from healthy donors in Egypt and, as controls, in Hong Kong were negative in both NT formats (Perera et al., 2013). Both studies emphasize that NT are less prone to unspecific reactivity and that the use of pseudotyped viruses has the added advantage of not requiring a BSL3 laboratory. Large-scale serological studies of the population in affected countries are urgently needed to further examine spread, prevalence and transmission of MERS-CoV.

Despite several attempts to find the source of the outbreak, the origin of MERS-CoV remains enigmatic. Several studies, based on nucleic acid detection assays, found closely related CoVs in different bat species in Africa, Saudi Arabia and Northern America (Annan et al., 2013; Anthony et al., 2013; Ilhete et al., 2013; Memish et al.,...
In parallel with PCR-based methods we took a serological approach and screened livestock animals from MERS-CoV-linked (Oman) and unlinked regions (Spain, The Netherlands). We showed that all tested dromedary camels from Oman as well as a few camels from the Canary Islands harbored MERS-CoV neutralizing antibodies (Reusken et al., 2013b). As the Canary Islands are not linked to any MERS cases this finding was surprising. Additionally we were able to identify MERS-CoV specific antibodies in camel sera from the United Arab Emirates (UAE) collected more than 10 years ago (Meyer et al., 2014). Importantly, since BCoV (a Beta-CoV of the A lineage) is commonly distributed among livestock, cross-neutralization of MERS-CoV by BCoV antibodies had to be excluded. Recently a study by Haagmans and colleagues could verify MERS-CoV infection in camels on a farm where human cases occurred by using RT-PCR detection methods (Haagmans et al., 2013). Still, since the genetic distance between the human and the camels MERS-CoV from that cluster was very small, it was not possible to determine whether camels were infected by humans or vice versa. The value of a MERS-S pseudotyped lentivirus-based neutralization test has been shown in an independent camel study conducted in Egypt, which also found a high percentage of neutralizing antibodies in those animals (Perera et al., 2013). In conclusion, these data highlight the problem of interpreting CoV serological assays, especially if whole virus-derived antigen is used, and further stresses that demonstrating neutralization is indispensable to ultimately confirm seroconversion to a specific CoV.

8. Conclusion

Serological assays have proven valuable for a multitude of investi gations, particularly as a complement to nucleic acid detection assays. Serology can help with the clarification of the identification of the source of infection, the clarification of the epidemiology including transmission pattern analysis, patient contact studies and the identification of asymptomatic cases. All of these tasks can only be achieved with specific and sensitive serological assays. However, for properly validated assays, well-characterized serum samples from patients are necessary and they are not available in an outbreak scenario.

Despite the large number of assays developed in the aftermath of the outbreak of SARS- and MERS-CoV, serological differentiation of HCoVs remains challenging. Overall, it can be concluded that problems with cross-reactivity are more likely to arise with a more conserved antigen, and will often manifest as false positive results. Whether ELISA or WB assays are the preferred screening tool depends on availability of molecular biological techniques, the exact study design as well as the number of samples. Compared to whole virus antigen, assays using recombinant proteins are in general more reliable and can be more easily standardized. Preferably, a recombinant serological assay should use an antigen which is highly immunogenic and provides epitopes specific for its virus species. In addition it is of importance that the protein is expressed in its natural conformation, i.e., displaying proper folding and glycosylation. As discussed above in case of coronaviruses only the S proteins combines all these features. Regardless of assay or antigen used, we recommend a thorough validation using a defined set of sera reactive with other HCoVs as well as a large number of negative serum samples from patients with other respiratory diseases. In any case, great care should be taken in selecting the most appropriate assay and the limitations of each assay should be considered when interpreting results. In our opinion to ultimately confirm serological results it is indispensable to perform a VNT as it is the most specific assay available.

To improve and coordinate the development of serological assays during future outbreaks of novel coronaviruses, a well-characterized subset of sera would be highly recommendable in order to implement a standardized protocol for validating new assays.

Acknowledgments

The work was funded by a FP7-European research project on emerging diseases detection and response, EMERPE, http://www.emerpe.eu/emp, contract number 223498 and ANTIGONE (contract number 278976). Author C.D. received infrastructural support as the German National Consulting Laboratory for Coronavirus. The Consulting Laboratory is appointed by the Robert Koch-Institut (RKI), Berlin, Germany.

References

Aburizaiza, A.S., Mattes, F.M., Azhar, E.I., Hassan, A.M., Memish, Z.A., Muth, D., Meyer, B., Lattewich, E., Muller, M.A., Drosten, C., 2014. Investigation of anti-middle East respiratory syndrome antibodies in blood donors and slaughterhouse workers in Jeddah and Makkah, Saudi Arabia, fall 2012. The Journal of infectious diseases 209 (2), 243–246.

Annan, A., Baldwin, H.J., Corman, V.M., Klose, S.M., Owusu, M., Nickram, E.E., Badu, E.K., Antii, P., Agbenyega, O., Meyer, B., Oppong, S., Sarkodie, Y.A., Kaliko, E.K., Lina, P.H., Godlevska, E.V., Reusken, C., Seebens, A., Glausa-Rauch, F., Vallo, P., Tschapka, M., Drosten, C., Drexler, J.F., 2013. Human betacoronavirus 2c EMC/2012-related viruses in bats, Ghana and Europe. Emerg. Infect. Dis. 19 (3), 456–459.

Areny, S.J., Ojeda-Flores, R., Rico-Chavez, O., Navarrete-Macias, I., Zambrana-Torrelio, C.M., Restal, M.K., Epstein, J.H., Tippins, T., Liang, E., Sanchez-Leon, M., Sotomayor-Bonilla, J., Aguirre, A.A., Avila-Flores, R., Medellin, R.A., Goldstein, T., Suzan, G., Daszak, P., Lipkin, W.I., 2013. Coronavirus in bats from Mexico. J. Gen. Virol. 94 (P 5), 1028–1038.

Bermingham, A., Chand, M.A., Brown, C.S., Aarons, E., Tong, C., Langrich, C., Hochschild, K., Brown, K., Galiano, M., Myers, R., Pebody, R.G., Green, H.K., Boddington, N.L., Gopal, R., Price, N., Newsholme, W., Drosten, C., Fouchier, R.A., Zambon, M., 2012. Severe respiratory illness caused by a novel coronavirus in a patient transferred to the United Kingdom from the Middle East, September 2012. Euro surveillance: bulletin Eurosurveillance on the maladies transmissibles 17 (40), 20290.

Bradburne, A.F., 1970. Antigenic relationships amongst coronaviruses. Arch. Gesamte Virusforsch. 31 (3), 352–364.

Buchholz, U., Muller, M.A., Nitsche, A., Sanewski, A., Weverning, N., Bauer-Balei, T., Bonin, F., Drosten, C., Schweiger, B., Wolff, T., Muth, D., Meyer, B., Buda, S., Krause, G., Schaade, L., Haas, W., 2013. Contact investigation of a case of human novel coronavirus infection treated in a German hospital, October–November 2012. Euro surveillance: bulletin Eurosurveillance on the maladies transmissibles 18 (8), p14006.

Buchholz, U.J., Bukreyev, A., Yang, L., Lamirande, E.W., Murphy, B.R., Subbarao, K., Collins, P.L., 2004. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. U.S.A. 101 (26), 9864–9869.

Burdelo, P.D., Dubovi, E.J., Simmonds, P., Medina, J.L., Henriques, J.A., Mishra, N., Wagner, J., Tokarz, R., Cullen, J.M., Iadarola, M.J., Rice, C.M., Lipkin, W.I., Kapoor, A., 2012. Serology-enabled discovery of genetically diverse hemorrhagic fevers in a new host. J. Virol. 86 (11), 6171–6178.

Carattoli, A., Di Bonito, P., Grasso, F., Giorgi, C., Blasi, F., Niedrig, M., Cassone, A., 2005. Recombinant protein-based ELISA and immuno-cytochemical assay for the diagnosis of SARS. J. Med. Virol. 76 (2), 137–142.

Chen, K-Y., Xue, X.R., 2003. SARS: epidemiology. Respirology 8, 59–114.

Chen, C.M., Tse, H., Wong, S.S., Woo, P.C., Lau, S.K., Chen, L., Zheng, B.J., Huang, J.D., Yuen, K.Y., 2009. Examination of serore prevalence of coronavirus HKU1 infection with 5 protein-based ELISA and neutralization assay against viral spike pseudotyped virus. J. Clin. Virol.: Off. Publ. Pan Am. Soc. Clin. Virol. 45 (1), 54–60.

Chen, H.K., Chan, J.F., Tse, H., Chen, L., Huang, C., Cai, J.P., Tsang, A.K., Xiao, X., To, K.K., Lau, S.K., Woo, P.C., Zheng, B.J., Wang, M., Yuen, K.Y., 2013. Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. J. Infect. 67 (2), 130–140.

Chen, K.H., Poon, L.L., Cheng, V.C., Guan, Y., Hung, I.F., Kong, J., Yam, L.Y., Seto, W.H., Yuen, K.V., Peiris, J.S., 2004a. Detection of SARS coronavirus in patients with suspected SARS. Emerg. Infect. Dis. 10 (2), 294–299.

Chen, P.K., Ng, K.C., Chan, R.C., Lam, R.K., Chow, V.C., Hui, M., Wu, A., Li, N., Yap, F.H., Cheng, F.W., Sung, J.J., Tam, J.S., 2004b. Immunofluorescence assay for serologic diagnosis of SARS. Emerg. Infect. Dis. 10 (3), 530–532.

Che, X.Y., Qiu, L.W., Liao, Z.Y., Wang, Y.D., Wen, K., Pan, Y.X., Hao, W., Mei, Y.B., Cheng, V.C., Yuen, K.Y., 2005. Antigenic cross-reactivity between severe acute respiratory syndrome–associated coronavirus and human coronaviruses 229E and OC43. J. Infect. Dis. 191 (12), 2033–2037.

Chen, X., Zhou, B., Li, M., Liang, X., Wang, H., Yang, G., Le, X., 2004a. Serology of severe acute respiratory syndrome: implications for surveillance and outcome. J. Infect. Dis. 189 (7), 1158–1163.

Chen, Z., Pei, D., Jiang, L., Song, Y., Wang, J., Wang, H., Zhou, D., Zhai, J., Du, Z., Li, B., Qiu, M., Han, Y., Guo, Z., Yang, R., 2004b. Antigenicity analysis of different regions of MERS-CoV.
the severe acute respiratory syndrome coronavirus nucleoprotein. Clin. Infect. Dis. 47, 998–1006.

Corman, V., Eckerle, I., Bleicker, T., Zaki, A., Landt, O., Eschbach-Bluemel, M., van Boheemen, S., Goyal, R., Ballhausen, M., Bestebroer, T., Muth, D., Muller, M., Drexler, J., Zamboon, M., Osterhaus, A., Fouchier, R., Drosten, C., 2012a. Detection of a novel human coronavirus by real-time reverse-transcription polymerase chain reaction. Euro surveillance: bulletin Europeen sur les maladies transmissibles 17 (39), pii: 20285.

Corman, V.M., Muller, M.A., Costabel, U., Timm, J., Binger, T., Meyer, B., Krehl, P., Latresche, E., Eschbach-Bluemel, M., Nitsche, A., Bleicker, T., Landt, O., Schweiger, B., Drexler, J.F., Osterhaus, A.D., Haagmans, B.L., Dittmer, U., Bonin, F., Wolff, T., Drosten, C., 2012b. Assays for laboratory confirmation of novel human coronavi-

Dijkman, R., Jefbink, M.F., Gaut, E., Rossen, J.W., Templeton, K.E., Kuipers, T.W., van der Hoek, L., 2012. The dominance of human coronavirus OC43 and Nl43 infections in NL3. J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol. 53 (2), 135–139.

Drexler, J.F., Corman, V.M., Muller, M.A., Lukashev, A.N., Gmyl, A., Coutard, B., Adam, A., Ritzi, D., Leijten, L.M., van Riel, D., Kallies, R., Klose, S.M., Glausa-Rausch, F., Binger, T., Annan, A., Adu-Sarkodie, Y., Oppong, S., Bourgarel, M., Rupp, D., Hoff-

Drosten, C., Seilmaier, M., Corman, V.M., Hartmann, W., Scheibe, G., Sack, S., Cugge-

Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H.R., Becker, S., Rabenau, H., Menger, K., Kolesnikova, L., Fouchier, R.A., Berger, A., Burgueiro, A.M., Cinat, J., Eickmann, M., Escriou, N., Grywna, K., Krammer, S., Manuguerra, J.C., Muller, S., Rickerts, V., Sturmer, M., Vieth, S., Klenk, H.D., Osterhaus, A.D., Schmitz, H., Doer, H.W., 2003. Identification of a novel coronavirus in patients with severe atypical pneumonia. New Engl. J. Med. 348 (23), 1967–1977.

Drosten, C., Seilmaier, M., Corman, V.M., Hartmann, W., Scheibe, G., Sack, S., Cugge-

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van der Werf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.

Eckerle, C., Jaffar, A., Benard, M., van derWerf, S., Brodt, H.R., van de Groep, P., others, 2013. Euro surveillance: bulletin Europeen sur les maladies transmissibles 18 (10), 2013–2017.
Maache, M., Komurian-Pradel, F., Rajaharison, A., Perret, M., Berland, J.L., Pouzol, S., Boudry, V., Lieutaud, G., Dufour, B., Dupont, L., Heuzey, A., de la Torre, J., Schauer, N., Roux, P., Osterhaus, A., Drosten, C., Bosch, J.B., Koopmans, M., 2011a. Specific serology for emerging human coronavirus by protein microarray. Euro surveillance: bulletin European sur les maladies transmissibles 16 (14), 20441.

Reusken, C.B., Haagmans, B.L., Keuten, A.G., Gutierrez, C., Godeke, G.J., Meyer, B., Muth, D., Raj, V.S., Vries, L.S., Cormann, V.M., Drexl, J.F., Smits, S.L., El Taher, Y.E., de Sousa, R., van Beek, J., Nowotny, N., van Maanen, K., Hidalgo-Hermoso, E., Bosch, B.J., Rottier, P., Osterhaus, A., Gortazar-Schmid, C., Drosten, C., Koopmans, M.P., 2011b. Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect. Dis. 11 (10), 859–866.

Rongan, M.A., Tabite, M., Durosinloun, B., Meyer, T., Plummer, A.J., Kayali, J.S., Sun, B.W., McKinley, K.Y., Firth, A.J., Dromedary Coro-29E coronavirus. Emerging Infect. Dis. 13 (11), 1719–1722.

Wernery, U., Fagbo, M., Crameri, R., Gmina, M., Drexler, G., Price, T., Dinneny, J., Fawzi, W.U., Tamin, A., and the WHO Study Group on Novel Coronavirus (2019-nCov) Serology. Lancet 395, 902–903.